X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5) 5
index medicus (5) 5
clinical neurology (4) 4
female (4) 4
male (4) 4
middle aged (4) 4
neurology (4) 4
deep brain stimulation - methods (3) 3
parkinson's disease (3) 3
adult (2) 2
aged (2) 2
deep brain stimulation (2) 2
deep brain stimulation - adverse effects (2) 2
deep-brain-stimulation (2) 2
disease progression (2) 2
genes (2) 2
life sciences (2) 2
movement disorders (2) 2
nervous system diseases (2) 2
neurosciences (2) 2
parkinson disease - therapy (2) 2
progression (2) 2
psychiatry (2) 2
quality-of-life (2) 2
severity of illness index (2) 2
studies (2) 2
subthalamic nucleus - surgery (2) 2
treatment outcome (2) 2
young adult (2) 2
5-year follow-up (1) 1
[scco.neur]cognitive science/neuroscience (1) 1
[sdv.neu.nb]life sciences [q-bio]/neurons and cognition [q-bio.nc]/neurobiology (1) 1
[sdv.neu.pc]life sciences [q-bio]/neurons and cognition [q-bio.nc]/psychology and behavior (1) 1
[sdv.neu.sc]life sciences [q-bio]/neurons and cognition [q-bio.nc]/cognitive sciences (1) 1
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (1) 1
[sdv] life sciences [q-bio] (1) 1
[sdv]life sciences [q-bio] (1) 1
abridged index medicus (1) 1
age (1) 1
alpha-synuclein - genetics (1) 1
alpha-synuclein - physiology (1) 1
alzheimers disease (1) 1
amyotrophic-lateral-sclerosis (1) 1
anxiety (1) 1
ataxia (1) 1
atrophy (1) 1
attention deficit disorder (1) 1
autonomic nervous system (1) 1
basal ganglia (1) 1
behavior - physiology (1) 1
biology (1) 1
biomedical research (1) 1
brain research (1) 1
case-control studies (1) 1
central nervous system diseases (1) 1
cerebellar ataxia (1) 1
cerebellum (1) 1
clinical trials (1) 1
complex traits (1) 1
complications (1) 1
controlled-trial (1) 1
cytogenetics (1) 1
disorders (1) 1
double-blind method (1) 1
dsm-iv (1) 1
dysfunction (1) 1
dyskinesias - psychology (1) 1
dyskinesias - therapy (1) 1
early fluctuations (1) 1
electric stimulation therapy - methods (1) 1
electrodes (1) 1
epidemiologic methods (1) 1
european clinical guidelines (1) 1
eye diseases (1) 1
genetic aspects (1) 1
genetic research (1) 1
genetic variance (1) 1
genetic variation (1) 1
genetics (1) 1
genetics and genomics (1) 1
genetics of disease (1) 1
genomes (1) 1
genomics (1) 1
genotype (1) 1
gilles de la tourette syndrome (1) 1
globus pallidus (1) 1
globus-pallidus (1) 1
group emsa-sg (1) 1
huntingtons-disease (1) 1
inclusion bodies (1) 1
levodopa - pharmacology (1) 1
medical research (1) 1
medical therapy (1) 1
medicine (1) 1
medicine, experimental (1) 1
mental disorders (1) 1
mesh: aged (1) 1
mesh: disease progression (1) 1
mesh: epidemiologic methods (1) 1
mesh: female (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Neurology, The, ISSN 1474-4422, 2017, Volume 16, Issue 8, pp. 610 - 619
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2009, Volume 4, Issue 9, p. e7114
Journal Article
Brain, ISSN 0006-8950, 1/2009, Volume 132, Issue 1, pp. 156 - 171
Parkinson plus diseases, comprising mainly progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) are rare neurodegenerative conditions. We... 
Multiple system atrophy | Progressive supranuclear palsy | Randomized controlled trial | Riluzole | Natural history | MULTIPLE SYSTEM ATROPHY | RICHARDSON-OLSZEWSKI-SYNDROME | GROUP EMSA-SG | NINDS NEUROPATHOLOGIC CRITERIA | AMYOTROPHIC-LATERAL-SCLEROSIS | NATURAL-HISTORY | STRIATONIGRAL DEGENERATION | SPORADIC OLIVOPONTOCEREBELLAR ATROPHY | HUNTINGTONS-DISEASE | NEUROSCIENCES | CLINICAL NEUROLOGY | PROGRESSIVE SUPRANUCLEAR PALSY | Neuroprotective Agents - therapeutic use | Parkinson Disease, Secondary - etiology | Severity of Illness Index | Prognosis | Riluzole - adverse effects | Supranuclear Palsy, Progressive - drug therapy | Humans | Middle Aged | Male | Multiple System Atrophy - complications | Psychometrics | Treatment Outcome | Disease Progression | Supranuclear Palsy, Progressive - complications | Epidemiologic Methods | Riluzole - therapeutic use | Female | Multiple System Atrophy - drug therapy | Aged | Multiple System Atrophy - diagnosis | Neuroprotective Agents - adverse effects | Supranuclear Palsy, Progressive - diagnosis | Index Medicus | Abridged Index Medicus | Supranuclear Palsy, Progressive | Neuroprotective Agents | Parkinson Disease, Secondary | Life Sciences | Multiple System Atrophy | Santé publique et épidémiologie | multiple system atrophy | Original | natural history | riluzole | progressive supranuclear palsy | randomized controlled trial
Journal Article
PLoS ONE, ISSN 1932-6203, 09/2009, Volume 4, Issue 9, p. e7114
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by parkinsonism, cerebellar ataxia and autonomic dysfunction.... 
Medical research | Nervous system diseases | Parkinson's disease | Genes | Genomics | Genetic research | Medicine, Experimental | Genetic aspects | Single nucleotide polymorphisms
Journal Article
Cerebral Cortex, ISSN 1047-3211, 11/2000, Volume 10, Issue 11, p. 1093
  Neuroimagery findings have shown similar cerebral networks associated with imagination and execution of a movement. On the other hand, neuropsychological... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.